BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/21/2025 9:22:11 AM | Browse: 34 | Download: 101
 |
Received |
|
2024-09-09 04:43 |
|
Peer-Review Started |
|
2024-09-09 04:43 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-11-21 06:33 |
|
Revised |
|
2024-12-01 13:21 |
|
Second Decision |
|
2024-12-25 02:48 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-12-25 11:21 |
|
Articles in Press |
|
2024-12-25 11:21 |
|
Publication Fee Transferred |
|
2024-12-02 07:28 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-01-02 02:43 |
|
Publish the Manuscript Online |
|
2025-01-21 09:22 |
| ISSN |
2218-4333 (online) |
| Open Access |
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Safety and effectiveness of induction chemoimmunotherapy followed by definitive radiotherapy or concurrent chemoradiotherapy in esophageal squamous cell carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Zhuo-Jun Wei, Lin Wang, Rui-Qi Wang, Yu Wang, Huan Chen, Hong-Lian Ma and Yu-Jin Xu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Natural Science Foundation of Zhejiang Province, China |
LGF21H160005 |
| Zhejiang Medical and Health Science and Technology Project, China |
2024KY049 |
|
| Corresponding Author |
Yu-Jin Xu, PhD, Professor, Department of Thoracic Radiotherapy, Zhejiang Cancer Hospital, No.1 East Banshan Road, Gongshu District, Hangzhou 310022, Zhejiang Province, China. xuyj@zjcc.org.cn |
| Key Words |
Esophageal squamous cell carcinoma; Radiotherapy; Immune checkpoint inhibitors; Chemotherapy; Patient safety; Treatment outcome |
| Core Tip |
This study highlighted the safety and effectiveness of combining induction chemotherapy with programmed cell death 1/programmed cell death ligand 1 inhibitors followed by definitive radiotherapy or chemoradiotherapy, for locally advanced unresectable esophageal squamous cell carcinoma. It identified induction therapy effectiveness and maintenance immunotherapy as key prognostic factors, emphasizing the need for further validation through prospective trials. |
| Publish Date |
2025-01-21 09:22 |
| Citation |
<p>Wei ZJ, Wang L, Wang RQ, Wang Y, Chen H, Ma HL, Xu YJ. Safety and effectiveness of induction chemoimmunotherapy followed by definitive radiotherapy or concurrent chemoradiotherapy in esophageal squamous cell carcinoma. <i>World J Clin Oncol</i> 2025; 16(3): 101251</p> |
| URL |
https://www.wjgnet.com/2218-4333/full/v16/i3/101251.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v16.i3.101251 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
